Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain
García-Carbonero, Rocío (Hospital 12 de Octubre (Madrid))
González Astorga, Beatriz (Hospital Universitario San Cecilio (Granada))
Vidal Tocino, Rosario (Complejo Asistencial Universitario de Salamanca (Castella i Lleó))
Contreras Toledo, Débora (Hospital Universitario Central de Asturias)
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Fernández Montes, Ana (Complexo Hospitalario Universitario de Ourense - CHUO)
Falcó, Esther (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears))
González Cordero, Marta (Hospital Universitario de Badajoz)
Reina Zoilo, Juan José (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Alonso Orduña, Vicente (Hospital Universitario Miguel Servet (Saragossa))
Rodríguez Salas, Nuria (Hospital Universitario La Paz (Madrid))
Gil Raga, Mireia (Hospital General Universitario de Valencia (València))
Pereira dos Santos, Cristina Maria (Institut d'Investigació Biomèdica de Bellvitge)
Páez, David (Institut de Recerca Sant Pau)
Anton-Pascual, Beatriz (Hospital 12 de Octubre (Madrid))
Aguilar Pereyra, Fernando (MSD Spain)
Morales, Pilar (MSD Spain)
Universitat Autònoma de Barcelona

Date:	2024
Abstract:	Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). We aimed to describe the dMMR/MSI-H testing practice in patients with mCRC in Spanish centers. Multicenter, observational retrospective study that included patients newly diagnosed with mCRC or who progressed to a metastatic stage from early/localized stages. Three hundred patients were included in the study from May 2020 through May 2021, with a median age of 68 years, and two hundred twenty-five (75%) had stage IV disease at initial diagnosis; two hundred eighty-four patients received first-line treatment, and dMMR/MSI-H testing was performed in two hundred fifty-one (84%) patients. The results of the dMMR/MSI-H tests were available in 61 (24%) of 251 patients before the diagnosis of metastatic disease and in 191 (81%) of 236 evaluable patients for this outcome before the initiation of first-line treatment. Among the 244 patients who were tested for dMMR/MSI-H with IHC or PCR, 14 (6%) were MMR deficient. The most frequent type of first-line treatment was the combination of chemotherapy and biological agent, that was received by 71% and 50% of patients with MMR proficient and deficient tumors, respectively, followed by chemotherapy alone, received in over 20% of patients in each subgroup. Only 29% of dMMR/MSI-H tumors received first-line immunotherapy. Our study suggests that a high proportion of patients with mCRC are currently tested for dMMR/MSI-H in tertiary hospitals across Spain. However, there is still room for improvement until universal testing is achieved. Trial registration: Not applicable.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Metastatic colorectal cancer ; Microsatellite instability ; Microsatellite stable ; Mismatch repair deficiency ; Real-world evidence
Published in:	Clinical & translational oncology, Vol. 26 Núm. 4 (april 2024) , p. 864-871, ISSN 1699-3055

DOI: 10.1007/s12094-023-03309-z
PMID: 37651021

8 p, 794.4 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles